Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOVE-FA: Vatiquinone for Friedreich ataxia
2020-002812-36Phase 2Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Friedreich ataxia (FA) comparing Vatiquinone with Placebo (2 arms). Primary endpoint: Change from baseline in modified Friedreich Ataxia Rating Scale (mFARS) at Week 72. Started Nov 2020; status: completed.
02
Drugs
vatiquinone
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on 2020-002812-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002812-36.